Periprocedural treatment with high-dose statins is known to have cardioprotective and pleiotropic effects, such as anti-thrombotic and anti-inflammatory actions.

-Objective: to determine whether preoperative rosuvastatin loading is independently associated with reduced myocardial ischemia and clinical outcomes in patients with stable angina undergoing isolated off-pump coronary bypass (OPCAB) in patients with acute coronary syndrome.

Study design

• Prospective, double-blinded, single-center study of each 117 subjects enrolled
• Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria will be enrolled preoperatively.
• Eligible subjects will be randomized 1:1 to A) High-dose rosuvastatin (n=117) vs. B) Placebo (n=117).
• The amount of preoperative administration of high-dose rosuvastatin will be 60mg of a total
• All subjects will undergo OPCAB procedure. - The primary and secondary endpoints will be compared at 30 days and 2 years postoperatively between two groups

Inclusion Criteria:

• The presence of acute coronary syndrome, including unstable angina, acute non-ST elevation myocardial infarction
• Age of 19 years or older
• A need for isolated surgical myocardial revascularization
• Patients with signed informed consent

Exclusion Criteria:

• Patients with combined surgery with coronary bypass grafting
• On-pump conversion
• Patients with any increase in liver enzymes
• Patients with history of liver or muscle disease.
• Patients with moderate renal dysfunction (creatinine>2.0mg/dl) or need for dialysis
• Re-do surgery
• Urgent/emergent surgery